Trending: Roche to Halt Lung-Cancer Trials After Treatment Misses Goals
11:26 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Roche said it plans to halt a mid- and late-stage clinical study for a combination of drugs to treat lung cancer after the treatment failed to meet the trial's primary efficacy goals. The company said its investigational drug tiragolumab in combination with Tecentriq and chemotherapy didn't meet the trial's objectives of progression-free survival and overall survival at its first interim analysis. The trial compared the treatment against Merck's Keytruda and chemotherapy. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)
(END) Dow Jones Newswires
July 05, 2024 11:41 ET (15:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks